Microdosing GLP-1s: what it is and how to dose it right

Key takeaways

• Microdosing means intentionally taking a smaller dose than the approved amount. The term was popularized largely by direct-to-consumer companies selling compounded GLP-1s that are not FDA-approved .
• Whether the low dose works is untested. The approved doses were studied in large trials; doses below them were not, so in the words of one university physician, the benefit at a microdose remains to be seen .
• The approved schedules already start low and ramp up slowly. Semaglutide (Wegovy) starts at 0.25 mg a week and climbs to 2.4 mg ; tirzepatide (Zepbound) starts at 2.5 mg . The labels already tell prescribers to individualize, so a supervised low dose is ordinary care, not a hack.
• The documented harm comes from the dose math. The FDA has logged adverse events, some requiring hospitalization, from dosing errors and confusion between milliliters, milligrams, and the units on an insulin syringe with compounded semaglutide .
• If you draw your own small dose, the fix is arithmetic, not guesswork: work out the mg per mL in your vial, the volume per dose, and the units on the syringe, then sanity-check it before you draw .

Where microdosing actually goes wrong: the draw, not the dose

So this piece does two things. It gives you the honest state of the evidence on the low dose, which is short because there is not much. Then it spends most of its time on what decides whether your microdose is what you think it is: the reconstitution and unit math you do at the kitchen counter.

What it means, and whether it works

Start with the plain version, because the word gets thrown around loosely. Cleveland Clinic puts it simply: the idea is that you intentionally take a reduced amount of a medication . For GLP-1s that means dosing below the schedule the manufacturer and the FDA settled on, sometimes well below it.

People try it for three reasons that all make sense: it costs less because it is less drug, it may come with milder side effects, and some want a small maintenance dose after they have hit their goal . None of those motivations are unreasonable. The honest problem is just that the low-dose version has not been tested.

An endocrinologist writing in STAT makes the point bluntly: the approved doses are the ones that were studied, microdosing has no legitimate long-term data behind it, and the term was popularized by direct-to-consumer companies selling compounded products that are not FDA-approved .

A university health system says the same thing more plainly: whether you see the benefit at low doses, in their words, remains to be seen . That is a real open question, and one worth weighing honestly before you spend money on it.

The dose math that trips people up

Here is the part the pitch skips. A microdose almost always comes from a compounded vial you reconstitute yourself, which means you, not a pharmacy, are turning a powder and some water into a number on a syringe. That hand-off is where the documented harm lives, and it is pure arithmetic, so it is fixable.

There are only three numbers, and they have to line up in order. Get the concentration first, then the volume, then the syringe units. Skip a step or mix up the labels and the error is not small, because at a microdose you are drawing tiny volumes where one misread line is a several-fold overdose.

1. Concentration first. Say your vial holds 5 mg of peptide and you add 2 mL of bacteriostatic water. That is 5 divided by 2, or 2.5 mg per mL. Nothing downstream is right until you know this number.
2. Then the volume. Want to draw 0.25 mg from that 2.5 mg/mL vial? That is 0.25 divided by 2.5, which is 0.1 mL.
3. Then the syringe units. A standard U-100 insulin syringe is marked in units where 100 units is 1 mL, so 0.1 mL is 10 units. That 10 is the line you actually draw to.
4. Sanity-check before you push. If a microdose lands at 50 or 100 units, you have almost certainly slipped a decimal or read mg as units. Stop and redo the math.

Vet the vial, not your own decision

Here is where skepticism actually belongs, and it is not aimed at you. Compounded GLP-1s are not FDA-approved, which means no process verifies their strength, purity, or quality before they reach your fridge . Your numbers are only ever as good as what is really in the vial, so a clean calculation on a mislabeled product still gets you the wrong dose.

That is the thing worth being paranoid about: the vendor and the product, not the decision to manage it yourself. Compounded GLP-1 versus the labeled drug goes deeper on what you are buying and how the two differ.

Two paths wearing the same name

Microdosing gets argued about because it is really two different things sharing one label. Pull them apart and most of the noise goes away.

• A clinician keeping you on a low, individualized dose that works and that you tolerate. That is ordinary care, and the labels themselves tell prescribers to do it .
• Drawing your own sub-label dose from compounded product. The benefit at that dose is untested , and the real risk is the draw math the FDA flagged, which you control by being rigorous about it .

Both are paths real people take. If you are on the self-managed one, the move is not to wing it and not to talk yourself out of it. It is to get the concentration math right, vet the source, and check every draw.

The honest read

The low number on the syringe is not the scary part. The unstudied benefit is an open question you weigh for yourself, and the draw-it-yourself math is the documented risk, the one you can eliminate outright by doing the arithmetic and checking it before every dose.

So if you are microdosing compounded product: work out your mg per mL, your volume, and your units, write them down, and run them through the GLP-1 conversion and reconstitution calculators before you draw. That one habit is what separates a microdose from a case report.

For the unit conversions themselves, dosing units versus mg and mcg breaks them down, and GLP-1 side effects and what helps covers the milder-dose tradeoff people are chasing.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 6 entries, three FDA prescribing or safety documents (primary canon) plus reputable secondary sources (a university health system, Cleveland Clinic, and a named endocrinologist's commentary in STAT), acknowledged inline. Last reviewed 2026-06-16.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Semaglutide dose calculator - Run semaglutide-focused vial draw math.